コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 roving trust and mutual accountability among stakeholders.
2 ources and Services Administration and other stakeholders.
3 ited research, clinical, and family/advocate stakeholders.
4 ic indicators to generate value for multiple stakeholders.
5 ed prioritization exercise including all key stakeholders.
6 recognizing that all members of society are stakeholders.
7 ing the knowledge of allergic disease to all stakeholders.
8 on early engagement across sectors and among stakeholders.
9 thesis and verification of findings with key stakeholders.
10 s of cognitive distinctiveness among diverse stakeholders.
11 ogy, foundational science, and public health stakeholders.
12 tient communities: the so-called third-party stakeholders.
13 as well as more cooperation between all the stakeholders.
14 ould enhance the surgical experience for all stakeholders.
15 ith an illustrative sample of 12 third-party stakeholders.
16 rition researchers, practitioners, and other stakeholders.
17 statisticians, healthcare planners and other stakeholders.
18 ated bed nets were supported by the multiple stakeholders.
19 ists' ideals and practices when working with stakeholders.
20 cess included representation from a range of stakeholders.
21 th staff, patients, relatives, volunteers or stakeholders.
22 guidelines through the participation of key stakeholders.
23 and requests for NTP's products by external stakeholders.
24 ctive dialogue between researchers and other stakeholders.
25 ideo was developed in collaboration with key stakeholders.
26 geted video for AAs with input from multiple stakeholders.
27 deployed, these approaches encumber multiple stakeholders.
28 dinated concerted action of a large group of stakeholders.
29 nce trends and disseminate these data to AMR stakeholders.
30 ry and molecular biology students, and other stakeholders.
31 dependent on collaboration between multiple stakeholders.
32 l research, participants are key among those stakeholders.
33 (4) What is the risk tolerance of the stakeholders?
34 nal collaboration (are they talking to other stakeholders?).
35 involvement (6 reviews/overviews); involving stakeholders (5 reviews/overviews); leadership support (
37 technological problems that affect multiple stakeholders, a diversity of knowledge among communicato
38 a needs assessment, and input from multiple stakeholders:A rigorous process was undertaken to develo
39 More surprisingly, we show that informing stakeholders about the effectiveness of control methods
44 examples illustrate how the perspectives of stakeholders across the healthcare ecosystem can influen
45 d application of biosecurity measures by all stakeholders active in the APR, including surveillance f
46 eness among critical care clinicians and key stakeholders, advocating for workplace changes to promot
47 ditions, or aspects of health) that relevant stakeholders agree are essential to assess in all clinic
48 lder group in a two-stage Delphi survey (103 stakeholders), agreed upon in a consensus meeting (31 st
49 lder group in a two-stage Delphi survey (103 stakeholders), agreed upon in a two-day consensus meetin
52 r at high resolution can inform a variety of stakeholders along the value chain of the construction i
55 for Breast Health is a successful example of stakeholder and collaborator involvement-both internal a
56 , translation will require a team of engaged stakeholders and a systematic process from beginning (pr
59 laboration across scientific disciplines and stakeholders and between nations is a necessary conditio
60 collection of quality data, identifying key stakeholders and bringing them on board to ensure the ex
62 ocial, academic, professional and regulatory stakeholders and communities, and these efforts must be
63 ne development effort that included clinical stakeholders and conformed to the Institute of Medicine'
64 ne development effort that included clinical stakeholders and conformed to the Institute of Medicine'
65 a joint VA/DoD guideline including clinical stakeholders and conforming to the National Academy of M
66 t available evidence with input from various stakeholders and consistent with Centers for Medicare an
68 main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy
69 f this study was to obtain feedback from key stakeholders and end users to identify program strengths
74 s groups with national experts and community stakeholders and mothers; and 4) a review of policy and
75 re is a need for training both, nonallergist stakeholders and patients to improve the reaction identi
76 ositive impact PPPs can have on partners and stakeholders and provide guidance on the formation of PP
77 ne development effort that included clinical stakeholders and stroke survivors and conformed to the N
78 apting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values,
79 their introduction must be prioritized among stakeholders and the vulnerable populations exposed to t
80 DG, PH, and SP) did a survey of professional stakeholders and then used a scenario planning technique
81 n oncology can improve communication between stakeholders and ultimately provide a clearer interpreta
82 rd, we discuss the governance factors (e.g., stakeholders and users, networks sustainability and main
83 ers), agreed upon in a consensus meeting (31 stakeholders) and refined through a checklist pilot (34
84 reed upon in a two-day consensus meeting (31 stakeholders) and refined through a checklist pilot (34
85 ng collaboration with experts and a range of stakeholders, and be dependent on the emergence of new e
88 consensus conference that included experts, stakeholders, and national organization leaders was conv
90 derstanding and agreement on a problem among stakeholders; and c) guiding intervention and policy for
92 ciples contain specific actions that various stakeholders are already undertaking or should undertake
93 unications between neuroscientists and other stakeholders are different from those that characterize
94 framework of integrated responding, in which stakeholders as responsible and response-able parties co
95 timates that decompose the cost by different stakeholders (as proposed in our framework), that consid
96 much work remains to be done, by all cancer stakeholders at the systems level, to overcome historica
97 and risk management programs to benefit all stakeholders but particularly patients with food allergy
98 A risk calculator app was developed which stakeholders can access to identify high-risk IH patient
99 to establish and evaluate programs; and all stakeholders can use it to help allocate resources and m
104 s fall to patients and their caregivers, yet stakeholder concerns in these heterogeneous environments
105 utcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops in Boston (17 patients/c
106 d by both global literature and an extensive stakeholder consultation across all ecosystems, sectors
108 sation of activities on the basis of a broad stakeholder consultation organised by WHO and UNAIDS.
109 were selected and an inception meeting with stakeholder consultations was held to launch research an
110 cludes several steps related to diagnostics, stakeholder consultations, and implementing direct and i
113 stions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.
114 Voluntary sustainability standards (VSS) are stakeholder-derived principles with measurable and enfor
115 ve and taken as a set, allow a wide range of stakeholders (designers, policy-makers, and vehicle manu
117 stitutes a significant challenge for the key stakeholders due to the combined effects of chronic illn
119 such risks will help policy-makers and other stakeholders effectively use forests as natural climate
121 This study evaluates the effectiveness of a Stakeholder Engagement (SE) intervention in improving ou
127 ted a checklist of recommendations regarding stakeholder engagement: HEM modeling, including model st
130 ndents identified areas for improvement, our stakeholders felt that Virtual ACE empowered them and pr
132 coplastic Breast Consortium consisting of 63 stakeholders from 20 countries obtained consensus during
134 ance (the Alliance) convened a think tank of stakeholders from academia, government, industry, and pa
135 embryo editing developments, scientists and stakeholders from all nations should cooperate to take a
137 quires a multifaceted approach that includes stakeholders from multiple sectors to integrate best pra
138 Such a partnership would necessarily involve stakeholders from the mental health field, civil society
139 ough structured conversations via a range of stakeholders (general dental practitioners, patients, in
141 June 2018 and May 2019, we engaged a diverse stakeholder group (including directors of statewide heal
143 hich were assessed by an international multi-stakeholder group in a two-stage Delphi survey (103 stak
144 ere consulted upon by an international multi-stakeholder group in a two-stage Delphi survey (103 stak
145 ast 70% of the voting participants from each stakeholder group providing a score between 7 and 9.
148 ctured interviews with participants across 7 stakeholder groups including residents, family members,
150 present the narrative findings in 4 domains: stakeholder groups, net coverage and utilization, social
156 l framework (the health issue, intervention, stakeholders, health system, and context) to assess faci
157 ps was conducted with national and community stakeholders (i.e., child care workers and mothers) to u
159 ith sectors beyond health, included multiple stakeholders, implemented diversified strategies, and fo
161 Data were collected from a small number of stakeholders in a single clinical setting that may not b
162 ve roles, as well as with a variety of other stakeholders in academic, industry, and nongovernment or
165 cilitated through greater involvement of all stakeholders in discussions and decision-making in order
167 ined in-depth interviews with a range of key stakeholders in health and mental health, analysis of me
169 ement, the proposed changes will benefit all stakeholders in postdoc success-including research teams
170 ich can help identify the characteristics of stakeholders in sustainability planning and engagement.
171 k) established recently by the FDA and major stakeholders in the Drug Discovery field for the validat
173 dren's Fund (UNICEF), and other partners and stakeholders in the region and globally were significant
175 purpose is to outline practical actions for stakeholders in undergraduate education at the levels of
176 s of NAFLD in the Asian population to assist stakeholders in understanding NAFLD disease burden.
177 s to translation from the perspective of all stakeholders, in the context of biofluid, histopathology
180 Feedback on the PtDA was solicited from 26 stakeholders including patients, clinicians, and the man
181 ntists from across the globe, as well as key stakeholders including people affected by HBV, we have i
182 broad and informed discussion involving all stakeholders including researchers, clinicians, patients
185 Vascular Leaders Forum brought together 100 stakeholders, including an international group of repres
186 process; by involving key public and private stakeholders, including appropriate regulatory bodies an
188 Americans require input from a broad set of stakeholders, including clinicians and researchers from
189 Communication and coordination among key stakeholders, including healthcare facilities, public he
193 operative engagement of transplant community stakeholders, including pharmaceutical industry, academi
194 input as well as the action of a variety of stakeholders, including scholarly communities, funding a
199 n qualitative research methods, conducted 53 stakeholder interviews in 4 days using purposeful (admin
202 recommend this GL for use." The domains of "Stakeholder involvement" and "Rigor of Development" only
203 horization requires collective action by all stakeholders, it may significantly reduce administrative
204 ery demands continuous communication between stakeholders, iterative adjustment of therapy, and quali
205 ress in meeting voluntary targets, and other stakeholders made some progress on sodium-reduction acti
206 This report summarizes findings from the stakeholders meeting and seeks to establish a platform f
207 ican College of Cardiology (ACC) sponsored a stakeholders meeting on October 1 to 2, 2015, in Washing
208 with community advisory boards and convened stakeholder meetings with local community members and pr
209 nment of health care provider organizations, stakeholders must understand the implications of misalig
211 SN-affiliated countries with sampling of key stakeholders (national nephrology society leadership, po
212 We urge the CDC to consult with primary stakeholders of COVID-19 testing when making such impact
214 ablished scientific organizations, advice to stakeholders often relies on a few advisors, making them
215 drug development to guide industry and other stakeholders on formulations most needed for low-income
216 ng reliable outbreak forecasts and informing stakeholders on mitigation and preventive measures.
217 sies, as well as provides recommendations to stakeholders on necessary steps for improving the conduc
218 ychographic segmentation approach to segment stakeholders on potential barriers to a target behavior.
219 ors, development agencies, and country-level stakeholders, organised into hubs responsible for financ
220 ogy training programs and the efforts of the stakeholder organizations serve as an example of how a m
221 nutrition organizations, such as ASN, other stakeholder organizations, researchers, food and nutriti
222 the factors that influence it and conducted stakeholder outreach regarding publicly available inform
223 sible antibiotic use from the perspective of stakeholders outside healthcare facilities or patient co
224 the kinds of topics scientists work on with stakeholders, over scientific trade-offs that arise in t
227 ion of recovery that embraces a diversity of stakeholder perspectives about acceptable recovery goals
230 ucted semi-structured interviews with 30 key stakeholders (physicians, nurses, hospital leadership, n
231 escribes the efforts and vision of the multi-stakeholder Predict & Prevent Learning Collaborative of
232 e context and analyzing the role of relevant stakeholders prior to conducting the research, consideri
234 lopment could help discern discordance among stakeholder priorities; facilitate cooperation to align
235 awareness of NTP's work on CrVI by external stakeholders (proximal outcome) and citations of NTP's r
237 parent inconsistency between the optimism of stakeholders regarding mortality reductions and a low le
239 ic prioritization of research that addresses stakeholder-relevant knowledge gaps will accelerate effe
240 actionable richness with added value for all stakeholders: researchers, funders, repository managers,
242 eroperability of data to widen access to all stakeholders, seamless connectivity (an internet of thin
245 tidisciplinary assessment, involving several stakeholders such as a transplant hepatologist, transpla
246 ake continued effort and commitment from key stakeholders such as health care providers, patients, th
247 nning for Healthy People 2030 well underway, stakeholders such as healthcare professionals can embrac
249 ecialty-specific quality measures will allow stakeholders, such as patients and payers, to determine
253 his risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommen
254 entists, physicians, policymakers, and other stakeholders that are working to improve access to innov
257 proposed recommendations; engaged dozens of stakeholders through a survey of these proposed recommen
258 providers, utilities, regulators, and other stakeholders to accelerate the adoption of innovative te
259 culosis by 2035, we call on all tuberculosis stakeholders to act to accurately diagnose and treat tub
260 sensus conference was convened including key stakeholders to address genetic counseling and testing,
263 entified and highlighted to empower relevant stakeholders to collaborate in designing and conducting
264 ium gathered a diverse group of more than 50 stakeholders to develop consensus on a core set of data
266 rne diseases is collaboration among multiple stakeholders to develop, implement, and evaluate initiat
268 survey should prompt a dialog among relevant stakeholders to establish a cohesive set of core compete
269 des a method for cities, counties, and other stakeholders to evaluate the potential benefits and cost
271 l be provided to local, national, and global stakeholders to inform strategies to reduce perinatal an
272 for the American Heart Association and other stakeholders to make rural populations a priority in pro
273 potential reactions by the public and other stakeholders to reproductive modification in forest plan
274 ns about the ability of parliament and other stakeholders to scrutinise and oversee government action
275 blic-private partnerships or consortia allow stakeholders to share expertise, resources, and data in
277 ther newer techniques, and (5) commitment of stakeholders to use of guideline documents to increase a
278 surements, and engage surgeons and all other stakeholders to work together to advance the science of
280 A research summit was held with multiple stakeholders under the auspices of the American College
281 to strategically direct resources, maximize stakeholder uptake of resulting knowledge and minimize t
283 escribes the efforts and vision of the multi-stakeholder Value-Based Models Learning Collaborative of
284 to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a con
286 ogram analysis, and interviews with relevant stakeholders were conducted to understand key drivers of
287 aborative process with diverse international stakeholders, which provides a foundation for endorsemen
289 Interviews included 50 NICU mothers and 59 stakeholders who provide services to these mothers or th
292 ding of the difficulties confronted by other stakeholders will help radiologists continue to collabor
293 ed here can provide clinicians and other key stakeholders with concrete insights, tools, and strategi
295 s is to provide measure developers and other stakeholders with guidance on the standards used by the
296 nsformation, by consolidating actions of all stakeholders, with the ultimate goal of evidence-based,
297 h care-associated infection (HAI) prevention stakeholders within states and improving HAI prevention
298 lso be disseminated to the local government, stakeholders within the community, and the population wi
300 comprehensive list of topics that a range of stakeholders would perceive as valid, important, and rel